Nine patients with anti‐neutrophil cytoplasmic antibody‐positive vasculitis successfully treated with rituximab
Open Access
- 23 May 2005
- journal article
- Published by Wiley in Journal of Internal Medicine
- Vol. 257 (6), 540-548
- https://doi.org/10.1111/j.1365-2796.2005.01494.x
Abstract
Objectives. Rituximab (RIT) is a monoclonal anti-CD20 antibody, which depletes B-lymphocytes but not plasma cells. RIT is used for treatment of B-cell lymphomas, but has also shown beneficial effects in autoimmune diseases. In this case series RIT was used in anti-neutrophil cytoplasmic antibody (ANCA)-positive vasculitis. Design. Case series with a structured follow-up of treated patients. Setting. Departments of Nephrology and Rheumatology of a university hospital. Subjects. Two women with myeloperoxidase-ANCA-positive microscopic polyangiitis and seven patients (five men and two women) with proteinase 3-ANCA-positive Wegener's granulomatosis. All patients were resistant to conventional therapy or had relapsed repeatedly after cessation of cyclophosphamide (Cyc). Interventions. The cases were treated with intravenous infusions of RIT once a week two times (three cases) or four times (six cases). To prevent formation of antibodies to RIT, mycophenolate mofetil (five patients), azathioprine (one patient), or a short course of Cyc (two patients) were added or allowed to continue. Main outcome measures. Remission at 6 months assessed with Birmingham vasculitis activity score. The cases were followed 6–24 months and relapse rate was also noted. Results. Eight of nine patients responded completely and one case responded partially. Pulmonary X-ray improved (four cases), progress of lower extremity gangrene stopped (one case), remission of neuropathy was stable (one patient), renal vasculitis went into remission (two cases), and severe musculoskeletal pain improved (one case). Minor relapse in the nose occurred in two cases. No adverse events or major infections were noted. Conclusion. RIT seems promising and safe in ANCA-positive vasculitis, and controlled studies should be conducted.Keywords
This publication has 19 references indexed in Scilit:
- B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose‐escalation trial of rituximabArthritis & Rheumatism, 2004
- Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid ArthritisNew England Journal of Medicine, 2004
- Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritisArthritis & Rheumatism, 2003
- The role of B cells in rheumatoid arthritisCurrent Opinion in Rheumatology, 2003
- The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosusArthritis & Rheumatism, 2003
- An open study of B lymphocyte depletion in systemic lupus erythematosusArthritis & Rheumatism, 2002
- Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletionAnnals Of The Rheumatic Diseases, 2002
- Treating human autoimmune disease by depleting B cellsAnnals Of The Rheumatic Diseases, 2002
- B-lymphocyte depletion therapy in rheumatoid arthritis and other autoimmune disordersBiochemical Society Transactions, 2002
- Nomenclature of Systemic VasculitidesArthritis & Rheumatism, 1994